Oral Anticoagulant Therapy and Skin Necrosis: Speculations on Pathogenesis

  • Carl G. Becker


Warfarin or Coumadin induced necrosis of the skin was first recognized in 19521 and since that time, several hundred cases have been described.


Anticoagulant Activity Skin Necrosis Oral Anticoagulant Therapy Acalculous Cholecystitis Skin Fold Thickness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H. Verhagen, Local haemorrhage and necrosis of the skin and underlying tissues during anticoagulant therapy with Dicumarol or Dicumacyl, Acta Med Scand 148:453 (1954).PubMedCrossRefGoogle Scholar
  2. 2.
    J. R. Horn, L. H. Danziger, and R. J. Davis, Warfarin induced skin necrosis: Report of four cases, Am J Hosp Pharm 38:1763 (1981).PubMedGoogle Scholar
  3. 3.
    J. Koch-Weser, Coumarin necrosis, Ann Int Med 68:1365 (1968).PubMedCrossRefGoogle Scholar
  4. 4.
    A. C. Weinberg, G. Lieskovsky, W. G. McGehee, and K. G. Skinner, Warfarin necrosis of the skin and subcutaneous tissue of the male external genitalia, J Urology 130:352 (1983).Google Scholar
  5. 5.
    A. W. Broekmans, R. M. Bertina, and E. A. Loeliger, Protein C and the development of skin necrosis during anticoagulant therapy, Thrombosis and Haemostasis 49:251 (1983).PubMedGoogle Scholar
  6. 6.
    W. G. McGehee, T. A. Klotz, D. J. Epstein, and S. I. Rapaport, Coumarin necrosis associated with hereditary protein C deficiency, Ann Intern Med 101:59 (1984).PubMedCrossRefGoogle Scholar
  7. 7.
    A. W. Broekmans, J. J. Veltkamp, and R. M. Bertina, Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families, N Engl J Med 309:340 (1983).PubMedCrossRefGoogle Scholar
  8. 8.
    C. T. Esmon, Protein C: Biochemistry, physiology, and clinical implications, Blood 62:1155 (1983).PubMedGoogle Scholar
  9. 9.
    J. H. Griffin, B. Evatt, and T. A. Zimmerman, Deficiency of protein C in congenital thrombotic disease, J Clin Invest 68:1370 (1981).PubMedCrossRefGoogle Scholar
  10. 10.
    P. C. Comp, and C. T. Esmon, Recurrent venous thromboembolism in patients with a partial deficiency of protein S, N Engl J Med 311:1525 (1985).CrossRefGoogle Scholar
  11. 11.
    S. Vigano, P. M. Manucci, S. Solinas, B. Botasso, and G. Mariani, Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy, Br J Haematol 57:213 (1984).PubMedGoogle Scholar
  12. 12.
    S. Vigano-D’Angelo, P. C. Comp, C. T. Esmon, and A. D’Angelo, Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states, J Clin Invest 77:416 (1986).PubMedCrossRefGoogle Scholar
  13. 13.
    V. Rose, H. C. Kwaan, K. Williamson, D. Hoppensteadt, J Walenga, and J. Fareed, Protein C antigen deficiency and warfarin necrosis, Am J Clin Path 86:653 (1986).PubMedGoogle Scholar
  14. 14.
    F. J. Walker, Identification of a new protein involved in the regulation of the anticoagulant activity of activated protein C, J Biol Chem 261:1094 (1986).Google Scholar
  15. 15.
    V. Hofmann, and P. G. Frick, Repeated occurrence of skin necrosis twice following coumarin intake and subsequently during decrease of Vitamin K dependent coagulation factors associated with cholestosis, Thrombosis and Haemostasis 48:245 (1982).PubMedGoogle Scholar
  16. 16.
    R. N. Everett, and F. L. Jones Jr. , Warfarin-induced skin necrosis: A cutaneous sign of malignancy? Postgrad Med 79:97 (1986).PubMedGoogle Scholar
  17. 17.
    S. N. Gitel, R. C. Stephenson, and S. Wessler, The activated factor X-antithrombin III reaction rate: A measure of the increased thrombotic tendency induced by estrogen containing oral contraceptives, Haemostasis 7:10 (1978).PubMedGoogle Scholar
  18. 18.
    T. W. Meade, Y. Sterling, H. Wiekes, and P. M. Mannucci, Effects of oral contraceptives and obesity on protein C antigen, Thrombosis and Haemostasis 53:198 (1985).PubMedGoogle Scholar
  19. 19.
    S. Wessler, Unpublished observation.Google Scholar
  20. 20.
    S. Wessler, S. M. Reimer, and M. D. Sheps, Biologic assay of thrombosis-inducing activity in human serum, J Appl Physiol 14:943 (1960).Google Scholar
  21. 21.
    P. Andrade-Gordon, and S. Strickland, Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen, Biochem 25:4033 (1986).CrossRefGoogle Scholar
  22. 22.
    J. C. Hall, D. McConahay, D. Gibson, J. Crockett, and R. Conn, Heparin necrosis. An anticoagulation syndrome, JAMA 244:1831 (1980).PubMedCrossRefGoogle Scholar
  23. 23.
    R. Levi, A. A. Chenouda, J. P. Trzeciakowski, Zhao-Gui Guo, L. M. Aarronson, R. D. Luskind, C. H. Lee, W. Gay, V. A. Subramanian, J. C. McCabe, and J. C. Alexander, Dysrhythmias caused by histamine release in guinea pig and human hearts, Klin Wochenschr 60:965 (1982).PubMedCrossRefGoogle Scholar
  24. 24.
    H. L. Meier, A. P. Kaplan, L. M. Lichtenstein, S. D. Revak, C. G. Cochrane, and H. H. Newball, Anaphylactic release of a pre-kallikrein activator from human lung in vitro, J Clin Invest 72:574 (1983).PubMedCrossRefGoogle Scholar
  25. 25.
    C. G. Becker, and T. Dubin, Activation of factor XII by tobacco glycoprotein, J Exp Med 146:457 (1977).PubMedCrossRefGoogle Scholar
  26. 26.
    L. Dillon, F. Glenn, and C. G. Becker Induction of acalculous cholecystitis and pneumonitis in dogs following inhalation of constituents of cigarette smoke condensate, Am J Path 109:253 (1982).PubMedGoogle Scholar
  27. 27.
    T. Francus, L. C. Thompson, B. Y. Rubin, M. K. Crow, G. W. Siskind, and C. G. Becker., Tobacco glycoprotein is a potent inducer of IL-1 production. (Manuscript in preparation.)Google Scholar
  28. 28.
    C. G. Becker, T. Dubin, and H. P. Wiedemann, Hypersensitivity to tobacco antigen, Proc Natl Acad Sci 73:1712 (1976).PubMedCrossRefGoogle Scholar
  29. 29.
    T. Francus, G. W. Siskind, and C. G. Becker, Role of antigen structure in the regulation of IgE isotype expression, Proc Natl Acad Sci 80:3430 (1983).PubMedCrossRefGoogle Scholar
  30. 30.
    R. F. Kein, and C. G. Becker, Selective expression of IgE reactive with tobacco glycoprotein in human sera, Fed Proc 45:225 (1986).Google Scholar
  31. 31.
    A. Firpo, M. J. Polley, and C. G. Becker, The effect of tobacco derived products on the human complement system, (Abstract) Immunobiology 164:318 (1984).Google Scholar
  32. 32.
    R. R. Kew, B. Ghebrehewet, and A. Janoff, Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement, J Clin Invest 75:1000 (1985).PubMedCrossRefGoogle Scholar
  33. 33.
    A. Firpo, F. Field, D. Wellner, F. Infante, C. G. Becker, and M. J. Polley, On the chemical characterization of a low molecular weight component of cigarette smoke which activates the alternative pathway of complement, (Abstract) in: “Complement: Laboratory and Clinical Research. XIIth International Complement Workshop,” ed., J. S. Cooper, S. Karger, Basel, p. 25, (1985).Google Scholar
  34. 34.
    S. H. Tannenbaum, R. Fink, and D. B. Cines, Antibody and immune complexes induce tissue factor production by human endothelial cells, J Immunol 137:1532 (1986).PubMedGoogle Scholar
  35. 35.
    T. S. Edgington, H. Helin, S. A. Gregory, G. Levy, D. S. Fair, and B. S. Schwartz, Cellular pathways and signals for the induction of biosynthesis of initiators of the coagulation protease cascade by cells of the monocytic lineage, in: “Mononuclear Phagocytes,” R. van Furth ed., Martinus Nijhoff, boston pp 687–696 (1985).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Carl G. Becker
    • 1
  1. 1.Cornell University Medical CollegeNew YorkUSA

Personalised recommendations